Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO) Files An 8-K Unregistered Sales of Equity SecuritiesItem 3.02.
On July 14, 2017, to a prior agreement, the Company delivered to an unaffiliated investor 357,143 shares of its common stock at a price of $0.14 per share and issued to such investor 267,857 Class A Warrants exercisable at $0.175 per share for a period of five years, for an aggregate of $50,000.
On July 18, 2017, to a prior agreement, the Company delivered to an unaffiliated investor 178,571 shares of its common stock at a price of $0.14 per share and issued to such investor 133,929 Class A Warrants exercisable at $0.175 per share for a period of five years, for an aggregate of $25,000, to an agreement dated May 31, 2017.
On August 3, 2017, unaffiliated investors converted portions of existing notes into 9,059,107 shares of its common stock at a conversion price of $0.18 and issued to such investors Class A Warrants exercisable at $0.18 per share for a period of five years and Class B Warrants exercisable at $1.00 per share for a period of three months, for an aggregate of $1,630,639.
On August 3, 2017, to prior agreements, the Company:
| · | delivered to an unaffiliated investor 200,000 shares of its common stock at a price of $0.16 per share and issued to such investor 150,000 Class D Warrants exercisable at $0.175 per share for a period of two years, for an aggregate of $32,000; |
| · | delivered to an unaffiliated investor 2.5 million shares of its common stock at a price of $0.24; |
| · | delivered to an unaffiliated investor 535,607 shares of its common stock at a price of $0.14 per share and issued to such investor 401,705 Class A Warrants exercisable at $0.175 per share for a period of two years, for an aggregate of $75,000; and |
| · |
delivered to an unaffiliated investor 462,142 shares of its common stock at a price of $0.14 per share and issued to such investor 346,607 Class A Warrants exercisable at $0.175 per share for a period of two years, for an aggregate of $64,700. |
On August 4, 2017, unaffiliated investors converted portions of existing notes into 4,885,780 shares of its common stock at a conversion price of $0.20 per share and issued to such investors 2,442,890 Class A Warrants exercisable at $0.23 per share for a period of five years and 2,442,890 Class B Warrants exercisable at $0.30 per share for a period of five years, for an aggregate of $977,156.
The securities were issued to the exemption from the registration requirements afforded by Section 4(a)(2) and Regulation D of the Securities Act.
About Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO)
Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing immunotherapy products to treat cancer. One of the product lines (DCVax-L) is designed to cover all solid tumor cancers in which the tumors can be surgically removed. Another product line (DCVax-Direct) is designed for all solid tumor cancers. The Company’s lead product, DCVax-L, is in an ongoing Phase III trial for diagnosed Glioblastome multiforme (GBM), with over 60 trial sites. Its second product, DCVax-Direct, is being studied in a 60-patient Phase I/II trial for all types of inoperable solid tumors. The 40-patient Phase I stage of the trial has been completed. The Company is working on preparations for Phase II trials of DCVax-Direct. The Company’s platform technology, DCVax, uses activated dendritic cells to mobilize a patient’s own immune system, including T cells, B cells and antibodies and natural killer cells, among others to attack cancer cells to attack their cancer.
